An Intermediate Expanded Use Trial of DFMO
Latest Information Update: 08 Aug 2024
At a glance
- Drugs Eflornithine (Primary)
- Indications Germ cell and embryonal neoplasms; Medulloblastoma; Neuroblastoma; Primitive neuroectodermal tumours; Rhabdoid tumour
- Focus Expanded access; Therapeutic Use
- 17 Jul 2023 Status changed from completed to recruiting.
- 03 Mar 2022 Status changed from recruiting to completed.
- 24 Jan 2020 New trial record